We just received an important update we would like to share with you from the University of Milan “Dino Ferrari Center”.
The report provides information on progress made in the scientific research of a possible approach to therapeutic approach for CMT2A which will be presented in a session at the 71st Congress of the American Academy of Neurology, the largest professional organization of neurologists in North America, to be held on May 4-10, 2019 in Philadelphia.
The presentation, entitled “RNAi/gene therapy combined approach and therapeutic strategy for Charcot-Marie-Tooth 2A” (Rizzo F, Bono S, Salani S, Bordoni A, Melzi V, Ruepp M, Pagliarani S, Barbullushi K, Abati E, Cordiglieri C, Bresolin N, Comi G, Nizzardo M, Corti S), will serve help to share the data and to focus the attention of a wide audience of researchers and clinicians on this disease.
Click here to read the report.
The commitment of our research group in recalling the scientific interest in this disease is also demonstrated by the recent publication in which we conducted a literature review concerning available in vitro and in vivo models of CMT2A and possible therapeutic approaches (BarbullushiK, Abati E, Federica Rizzo F, Bresolin N, Comi GP, Corti S. Disease modeling and therapeutic strategies in CMT2A: state of the art. in press Molecular Neurobiology).